President Trump promised to bring manufacturing back to America during his campaign.
Now major companies are putting their money where his mouth is.
And Donald Trump just secured a massive economic win that has Americans cheering.
Trump’s America First agenda sends pharmaceutical industry into overdrive
Pharmaceutical companies are falling in line with Donald Trump’s America First vision at a breathtaking pace.
In a stunning development that the mainstream media doesn’t want to talk about, major drug manufacturers are announcing tens of billions in new investments across the United States as Trump’s policies begin supercharging the economy.
Gilead Sciences just became the latest industry giant to announce a massive $11 billion boost to its planned U.S. spending, joining a tidal wave of pharmaceutical companies bringing production back to American soil.
President Trump has consistently emphasized the importance of bringing pharmaceutical manufacturing back to American soil throughout his presidency. His administration has made reshoring critical industries a cornerstone of its economic policy.
The announcement follows Trump’s executive order requiring federal agencies to prioritize purchasing American-made pharmaceuticals and medical supplies, sending a clear signal that the administration is serious about reshoring critical industries.
Big Pharma bets big on Trump’s manufacturing revival
The list of companies pledging enormous investments reads like a Who’s Who of the pharmaceutical world.
Johnson & Johnson announced a staggering $55 billion investment in manufacturing, research and development, and technology. Swiss drug giant Roche committed $50 billion to its U.S.-based operations, while Bristol Myers Squibb pledged $40 billion.
Indiana-based Eli Lilly revealed plans to more than double its domestic manufacturing capacity with a $27 billion investment that will create thousands of good-paying American jobs.
The administration has consistently framed pharmaceutical independence as a national security issue, moving aggressively to reduce America’s reliance on foreign countries for critical medicines.
The moves come as bipartisan concern grows about America’s dangerous dependence on foreign-made drugs and medical supplies. During the COVID pandemic, nearly 80% of active pharmaceutical ingredients were made overseas, primarily in China and India.
Trump reverses Biden-Harris pharmaceutical exodus
The pharmaceutical industry’s massive U.S. reinvestment represents a stunning reversal from the offshoring trend that accelerated under the Biden-Harris administration.
The pharmaceutical industry’s renewed investment in American manufacturing represents a significant shift from recent years, when companies frequently chose to build new facilities overseas rather than in the United States.
Trump’s critics initially mocked his promise to revitalize American manufacturing, claiming his tariff policies would backfire and drive prices higher. Instead, companies are responding exactly as Trump predicted – by moving production back to American soil to avoid tariffs and regulatory headaches.
Even traditional Trump critics in the industry are acknowledging his approach is working.
The pharmaceutical industry appears to be responding positively to the new administration’s policies, with company after company announcing major American investments within months of Trump’s return to office.
The pharmaceutical manufacturing revival is happening alongside similar announcements in steel, automobiles, and technology – industries Trump specifically targeted for revival during his campaign.
AbbVie announced a $10 billion investment over the next decade, adding four new manufacturing plants to its U.S. network. Merck & Co. revealed plans for $9 billion in new manufacturing facilities, including a state-of-the-art biologics plant in Delaware.
Not to be outdone, Novartis is committing $23 billion to build or expand ten manufacturing facilities across the country.
These investments are expected to create thousands of high-paying jobs across America, including in rural communities that have historically suffered from manufacturing job losses. Many of these positions typically offer salaries well above the national average, potentially transforming economic prospects in regions that have struggled in recent decades.
After decades of pharmaceutical manufacturing moving overseas, Trump’s aggressive America First policies are bringing these critical industries home where they belong.
